http://www.neurenpharma.com//irm/sh...unceGuid=3992c756-6537-47c3-92ee-06a33bbfcee9
Damn.
The trial did not demonstrate a difference between drug and placebo in the 3 core efficacy measures, which were the Extended Glasgow Outcome Scale (GOS-E), the Mayo-Portland Adaptability Inventory (MPAI-4) and mortality.
The overall rate of mortality in the INTREPID trial was lower than was observed in prior trials, but there was no significant difference between drug and placebo.
Ann: Results of Phase 2 trial in moderate to severe TBI-NEU.AX, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.10 |
Change
-0.800(5.76%) |
Mkt cap ! $1.629B | |||
| Open | High | Low | Value | Volume |
| $13.95 | $13.96 | $12.88 | $9.534M | 725.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 266 | $13.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.15 | 1619 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |